FDA Is Ending Self-Affirmed GRAS: What Canadian Suppliers Must Do

For sixty-five years a company could decide on its own that a food ingredient was Generally Recognized as Safe, place it on the United States market, and never tell the Food and Drug Administration. That option, known as self-affirmed GRAS, is now proposed for removal. On 11 August 2026 FDA published a proposed rule that would make GRAS notification mandatory for the first time in the history of the framework. For Canadian ingredient suppliers who sell into the United States, this is not a distant American story. It changes how you will need to document, defend and file the safety of every new ingredient.

This article explains what the proposed rule does, who it affects, the transition pathway written into it, and the question every Canadian company asks next: does a United States GRAS conclusion mean anything in Canada? The short answer is no, and understanding why matters as much as the rule itself.

Executive summary

In brief: FDA's proposed rule, published at 91 FR 51834 on 11 August 2026, would replace the voluntary GRAS notification programme with a mandatory one. Any company introducing a substance as GRAS after the final rule takes effect would have to file a notice with FDA rather than rely on a private expert-panel conclusion. Comments are open until 9 December 2026. The rule reaches human food under 21 CFR Part 170 and animal food under 21 CFR Part 570.

What self-affirmed GRAS is, and what FDA wants to change

What it is: GRAS stands for Generally Recognized as Safe. It is the legal category that lets a food substance skip the formal food-additive approval process when qualified experts generally agree it is safe for its intended use. Self-affirmed GRAS means the company reached that conclusion privately, often through its own expert panel, and chose not to notify FDA. The proposed rule would close that private route and require a notice for every new GRAS substance.

The GRAS concept dates to a 1958 amendment to the United States Food, Drug, and Cosmetic Act. Since 2016 FDA has run a voluntary notification programme under which companies could, but were not required to, submit their GRAS conclusions for FDA review. Critics have long argued that the voluntary design let substances reach grocery shelves with no federal visibility. The proposal follows a March 2025 direction from the Secretary of Health and Human Services to eliminate the pathway by which GRAS substances are marketed without notification.

For Canadian companies the relevant point is practical, not philosophical. If your ingredient enters the United States on a self-affirmed conclusion today, the same ingredient would need a full GRAS notice once the rule is final. The safety story that used to sit in an internal file would have to survive an FDA review. Suppliers who also sell supplemented foods should read this alongside our guide to supplemented foods compliance in Canada, because the ingredient dossiers overlap.

What the proposed rule actually changes

Why it matters: The rule does more than switch notification from optional to mandatory. It rebuilds the mechanics of how a GRAS conclusion is filed, translated and preserved, and it removes an older pathway entirely. The table below summarises the core provisions in the proposal.

Two operational changes deserve attention. Mandatory electronic submission means the era of a paper dossier sitting in a filing cabinet is over. Mandatory English translation means any safety study, toxicology report or expert statement generated in another language must be translated before it can support a notice. Companies that rely on studies published in French or other languages will need to plan translation time and cost into every submission.

Who is affected, and why Canadian suppliers are directly in scope

Who it affects: The rule reaches food and beverage manufacturers, supplemented food makers, natural health product and dietary supplement ingredient suppliers, flavour and additive houses, and animal and pet food manufacturers. Any Canadian company that has been selling an ingredient into the United States on a self-affirmed conclusion is exposed, because the self-affirmation escape hatch is exactly what the rule removes.

Canadian exporters already navigate United States requirements through the dietary supplement current good manufacturing practices in 21 CFR Part 111 and the Foreign Supplier Verification Program. The GRAS proposal adds a third pressure point at the ingredient level. It also raises the evidentiary bar for the companies that supply you, which is why a disciplined supplier qualification programme now needs to capture the GRAS status of each ingredient, not just its certificate of analysis.

A common inspection and diligence finding is that a company cannot produce the basis for a GRAS claim on request. Under a voluntary system that gap was survivable. Under a mandatory one it is a blocker: without a notice on file, the substance is not lawfully marketed. Firms should expect buyers, contract manufacturers and their own quality teams to start asking for the GRAS notice number long before any final rule takes effect.

The Subpart F transition pathway

What to do: The proposal includes a new Subpart F that would give substances already in interstate commerce before the effective date a time-limited route into the notification system, rather than forcing them off the market on day one. If you have ingredients on the United States market today, your first task is to identify which of them rely on self-affirmed conclusions and would need to use this transition window.

The transition pathway is not automatic. It will carry its own timing, content and filing expectations, and the details will be shaped by the comments FDA receives before 9 December 2026 and by the final rule. The practical risk is a company assuming its legacy ingredient is safe forever, missing the transition window, and finding it has no notice on file when the grace period closes. Treat the transition as a project with a deadline, not a formality.

Not sure whether your ingredient qualifies for the Subpart F transition pathway? MFLRC can assess your existing GRAS file against the proposed requirements and tell you where the gaps are.

Does a US GRAS conclusion mean anything in Canada?

Direct answer: No. A GRAS conclusion has no legal standing in Canada. Health Canada regulates food additives through its own Food Additive submission process and assesses new ingredients as novel foods where applicable. A substance that is GRAS in the United States may still require a food additive submission or a novel food assessment before it can be sold in Canada.

This matters because the FDA proposal will pull a large volume of search and boardroom attention onto the word GRAS over the next several months. Canadian companies will hear that an ingredient is GRAS and assume it clears the Canadian border. It does not. Canada operates the Marketed Foods and Food Additive frameworks and, for genuinely new substances, the Novel Food regime. Ingredient integrity is also a live enforcement theme, as our review of the 2026 CFIA food fraud report shows. If you sell food and beverages into Canada, treat the United States and Canadian pathways as two separate files. Our food and beverages regulatory services map both.

The reverse is also true. A Canadian food additive approval or novel food decision does not create GRAS status in the United States. Companies operating in both markets should build a single ingredient dossier that can feed both a Canadian submission and a United States GRAS notice, rather than duplicating the science twice under different headings.

Compliance checklist

Use this checklist to prepare before the comment period closes and before any final rule takes effect.

• Inventory every ingredient you sell into the United States and record whether each relies on a self-affirmed GRAS conclusion or a filed GRAS notice.
• Flag any substance that entered interstate commerce before the anticipated effective date, since these are the candidates for the Subpart F transition pathway.
• Confirm your safety dossier is complete, current and structured to survive an FDA notification review rather than an internal panel conclusion.
• Identify any supporting study or expert statement that is not in English and plan the translation required under the proposed section 170.220.
• Check that you can produce the basis for each GRAS claim on request, including the identity of the experts and the data they relied on.
• Update supplier qualification records to capture the GRAS status and notice number of each purchased ingredient.
• For animal and pet food ingredients, run the same review against 21 CFR Part 570.
• Map the Canadian pathway separately: decide whether each ingredient needs a food additive submission or a novel food assessment.
• Decide whether to file a comment before 9 December 2026, particularly if the transition timing would affect a specific ingredient in your portfolio.

Common mistakes

• Assuming the rule is already in force. It is a proposal. Self-affirmed GRAS is still lawful until a final rule takes effect, but waiting until then to prepare leaves no runway.
• Treating a US GRAS conclusion as a Canadian clearance. Health Canada does not recognise GRAS. A separate Canadian assessment is often required.
• Forgetting animal food. Part 570 brings pet and animal food ingredients into the same regime, which surprises companies focused only on human food.
• Underestimating translation. Non-English studies must be translated to support a notice, and that adds time and cost to every submission.
• Confusing the dates. The HHS announcement was 10 August 2026, but the legal event is publication at 91 FR 51834 on 11 August 2026. Cite the Federal Register date.
• Missing the transition window. The Subpart F pathway is time-limited. A legacy ingredient with no notice on file when the window closes is no longer lawfully marketed.

Frequently asked questions

Is self-affirmed GRAS still legal?

Yes, for now. The 11 August 2026 rule is a proposal, not a final rule. Until a final rule takes effect, a company may still reach a self-affirmed GRAS conclusion. The direction of travel, however, is clearly toward mandatory notification, so preparing now is prudent.

When would the mandatory GRAS rule take effect?

No effective date is set yet. The comment period closes on 9 December 2026. A final rule would follow, with its own effective date and the Subpart F transition window for substances already in commerce.

Does a US GRAS conclusion apply in Canada?

No. Health Canada runs its own Food Additive and, where relevant, Novel Food assessments. A GRAS conclusion carries no legal weight in Canada, so a separate Canadian submission may be required before an ingredient can be sold.

What is the Subpart F transition pathway?

It is a new, time-limited route in the proposal that would let substances already in interstate commerce before the effective date come into the notification system rather than leaving the market immediately. Its exact timing and content requirements will be set by the final rule.

Does the rule cover animal food?

Yes. Alongside 21 CFR Part 170 for human food, the proposal amends 21 CFR Part 570 so that the same mandatory notification architecture applies to animal and pet food ingredients.

What should Canadian suppliers do before 9 December 2026?

Inventory your GRAS ingredients, assess whether each dossier could survive an FDA notification review, plan any translations, map the separate Canadian pathway, and decide whether to submit a comment. Companies that start now will have a filed, defensible position when the final rule arrives.

How MFLRC can help

MFLRC helps food, supplemented food, natural health product and ingredient companies prepare for the mandatory GRAS regime on both sides of the border. Our regulatory affairs, licensing and import and export services cover GRAS dossier preparation and FDA notification filing, ingredient regulatory strategy, gap assessments against the proposed requirements, supplier qualification, and comment submission before 9 December 2026. For Canadian market entry we align the United States file with the food additive and novel food routes, and our natural health product services connect ingredient work to site licence and labelling obligations.

If you are unsure whether your ingredients rely on self-affirmed conclusions, or whether they fit the Subpart F transition pathway, we can review your portfolio and give you a prioritised action list.

Conclusion

The end of self-affirmed GRAS is not yet law, but the proposal is detailed, the political direction is settled, and the comment clock is running to 9 December 2026. Companies that treat this as a four-month project rather than a future problem will be able to file confidently when the final rule lands, while those that wait may face a scramble to build dossiers and translations under a transition deadline.

For Canadian suppliers the two-market discipline is the theme to hold onto. A United States GRAS notice and a Canadian food additive or novel food decision are separate files built on shared science. Manage them together, verify each claim at the subsection level, and keep the evidence ready to produce on request.

Sources and references

• Federal Register, Substances Generally Recognized as Safe, 91 FR 51834 (11 August 2026), document 2026-16296, docket FDA-2025-N-3262.
• FDA, Generally Recognized as Safe (GRAS) programme page.
• Health Canada, Food additives, for the Canadian food additive submission framework.
• Health Canada, Novel foods, for the novel food assessment pathway.